Adagio Medical Holdings Inc

The company's capital structure is highly leveraged, with total liabilities of $61.8 million and total equity of -$53.7 million, resulting in a debt-to-equity ratio of -0.91. Liquidity is constrained, with only $2.05 million in cash and equivalents against $61.8 million in total liabilities, yielding a current ratio of 0.11. The negative net cash position after subtracting total debt raises concerns about short-term solvency.

Profitability metrics are deeply negative, with a net loss of $5.03 million and an operating loss of $6.66 million. Return on equity is 9.35%, but this is misleading due to the negative equity base. Return on assets is -6.23%, indicating poor asset utilization. These results fall well below the industry median for EBITDA margins and ROIC in the Advanced Medical Equipment & Technology sector.

The company operates as a single-segment entity with no disclosed geographic revenue breakdown. This lack of diversification increases exposure to regional regulatory shifts and reimbursement policy changes. The absence of segment reporting prevents assessment of growth drivers or risk concentrations.

Growth prospects are constrained by negative operating cash flow of $13.68 million and free cash flow of -$4.9 million. Capital expenditures of -$337,000 suggest asset disposals rather than expansion. With no revenue growth history provided and a current market cap of $20.0 million, the company faces significant challenges in scaling operations.

Risk factors include medium liquidity risk from negative working capital and a high debt load. Dilution risk is currently low, but the negative equity position could force equity financing in the near term. Analysts have assigned a mean price target of $3.50, implying 288% upside from the current market price of $0.90, but this is supported by only two "buy" ratings and no "strong buy" recommendations.

Recent filings show no material events in the last 90 days. The company's 10-K filing from 2023-04-02 disclosed ongoing clinical trials for its non-invasive glucose monitoring device, but no regulatory approvals have been announced. No earnings call transcripts are available for the last quarter.

Adagio Medical Holdings Inc (ADGM.O) has recorded new institutional holdings, marking a shift in its investor base. The most material change involves an investor (ID 465) adding 79,451 shares, valued at approximately $0.083 million, as of December 31, 2025. This addition represents a portfolio weight of roughly 0.00012%, signaling initial accumulation by this specific entity. Additional notable additions were detected for the quarter ending March 31, 2026. Investor ID 502 added 21,598 shares, valued at $0.025 million, while Investor ID 486 added a smaller position of 137 shares, valued at $0.00016 million. These transactions were all detected on June 20, 2026, indicating a cluster of new interest in the stock during this period. These changes are significant as they represent the first analysis for this ticker, meaning there is no prior basis for computing deltas against previous holdings. The emergence of these four top holders suggests early-stage institutional attention, although the absolute values remain small relative to typical large-cap benchmarks. The company currently operates with a lean structure, reporting only one officer and no analyst coverage. With zero index memberships and no prior analyst estimates or financial history available for comparison in this dataset, the new holder activity stands out as the primary indicator of market engagement for Adagio Medical Holdings Inc.

Analysts project 692.8% upside to a mean price target of $3.50, signaling strong expected recovery potential.

Cash conversion ratio of 2.72 is best-in-class, significantly exceeding the cohort median of 0.79.

Debt-to-equity ratio of -0.91 is best-in-class, reflecting a balance sheet with no net debt burden.

Current ratio of 2.44 indicates strong short-term liquidity, providing a buffer against immediate operational cash needs.

The company faces high credit risk, indicating significant concerns regarding its ability to meet financial obligations.

Operating margin of -26.2% places the firm in the bottom quartile, far worse than the cohort median of -0.27%.

Revenue remains negligible at $602,000, suggesting the business has not yet achieved meaningful commercial scale.

Revenue $0.00; Operating income +29,7% YoY.

• ▍Revenue $0.00
• ▍Operating income +29,7% YoY

Revenue $0.00, −100,0% YoY; Operating income +93,2% YoY.

• ▍Revenue $0.00, −100,0% YoY
• ▍Operating income +93,2% YoY
• ▍Net income +94,2% YoY
• ▍Free cash flow +95,5% YoY

Revenue $0.00, −100,0% YoY; Operating income +74,0% YoY.

• ▍Revenue $0.00, −100,0% YoY
• ▍Operating income +74,0% YoY
• ▍Net income +66,6% YoY
• ▍Free cash flow +67,5% YoY